15,860 Shares in Exscientia plc (NASDAQ:EXAI) Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC purchased a new stake in shares of Exscientia plc (NASDAQ:EXAI) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 15,860 shares of the company’s stock, valued at approximately $77,000.

A number of other institutional investors also recently modified their holdings of EXAI. Vanguard Personalized Indexing Management LLC bought a new position in shares of Exscientia in the second quarter worth about $54,000. Federated Hermes Inc. acquired a new stake in Exscientia in the 2nd quarter valued at approximately $115,000. EntryPoint Capital LLC increased its position in Exscientia by 22.8% in the 1st quarter. EntryPoint Capital LLC now owns 31,171 shares of the company’s stock worth $178,000 after buying an additional 5,784 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in shares of Exscientia during the second quarter worth approximately $256,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Exscientia by 108.8% in the second quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company’s stock valued at $1,981,000 after acquiring an additional 202,377 shares during the period. Institutional investors own 41.58% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on EXAI. TD Cowen restated a “hold” rating on shares of Exscientia in a report on Friday, August 9th. Barclays reaffirmed an “equal weight” rating and issued a $5.00 price target on shares of Exscientia in a report on Tuesday, August 13th.

Exscientia Price Performance

Shares of EXAI stock opened at $5.28 on Friday. The firm’s 50 day moving average price is $5.00 and its two-hundred day moving average price is $5.10. The stock has a market cap of $638.30 million, a PE ratio of -4.06 and a beta of 0.83. Exscientia plc has a 52-week low of $3.80 and a 52-week high of $7.91. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.93 and a current ratio of 5.93.

Exscientia (NASDAQ:EXAI) last posted its earnings results on Thursday, August 15th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.05). The firm had revenue of $5.60 million during the quarter. Exscientia had a negative return on equity of 37.56% and a negative net margin of 620.99%. As a group, analysts forecast that Exscientia plc will post -1.25 EPS for the current year.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.